Baidu
map

NCCN乳腺癌临床实践指南2016.2版(1)

2016-12-29 浮云 NCCN乳腺癌临床实践指南2016.2版

非浸润性乳腺癌: l小叶原位癌(LCIS-1) l导管原位癌(DCIS)检查和主要治疗(DCIS-1) l导管原位癌术后治疗和监测/随访(DCIS-2) l导管原位癌切缘状况(DCIS-A

王云 (浮云)好消息:鉴于众多肿瘤科同行提出对其他癌种指南中文版的需求,《指南解读》已经邀请来自天津肿瘤医院、北京301医院、南方医院、青岛大学附属医院等国内各大医院肿瘤科同行共同编译和审阅其他癌种最新NCCN指南,我们计划在未来2月完成NCCN官方网站40个癌种最新临床实践指南和支持治疗指南的编译工作。有意在第一时间拿到我们编译的所有最新指南中文版的同行,可加黄医生个人微信号30842121,我们将统一在2017年2月28日以电子版形式发送。考虑编译者团队在工作之余付出的大量辛苦工作,我们将向每位订制者收取360元(40个癌种)或100元(单个癌种)费用,敬请大家理解和支持!您也可以选择关注本公众号,免费阅读《指南解读》陆续推出的各癌种指南。非浸润性乳腺癌:l小叶原位癌(LCIS-1)l导管原位癌(DCIS)检查和主要治疗(DCIS-1)l导管原位癌术后治疗和监测/随访(DCIS-2)l导管原位癌切缘状况(DCIS-A)浸润性乳腺癌:l临床分期,检查(BINV-1)l临床分期为I、IIA、IIB或T3,N1,M0(BINV-2)期的局部治疗l全身辅助治疗   &n

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1797750, encodeId=e1911e97750d9, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Oct 25 08:25:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2031162, encodeId=00fe203116211, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Aug 22 14:25:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319826, encodeId=097113198262c, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323793, encodeId=496b1323e9316, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572101, encodeId=9c8315e2101a7, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1797750, encodeId=e1911e97750d9, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Oct 25 08:25:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2031162, encodeId=00fe203116211, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Aug 22 14:25:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319826, encodeId=097113198262c, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323793, encodeId=496b1323e9316, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572101, encodeId=9c8315e2101a7, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1797750, encodeId=e1911e97750d9, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Oct 25 08:25:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2031162, encodeId=00fe203116211, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Aug 22 14:25:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319826, encodeId=097113198262c, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323793, encodeId=496b1323e9316, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572101, encodeId=9c8315e2101a7, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1797750, encodeId=e1911e97750d9, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Oct 25 08:25:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2031162, encodeId=00fe203116211, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Aug 22 14:25:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319826, encodeId=097113198262c, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323793, encodeId=496b1323e9316, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572101, encodeId=9c8315e2101a7, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1797750, encodeId=e1911e97750d9, content=<a href='/topic/show?id=cccd23e31c0' target=_blank style='color:#2F92EE;'>#乳腺癌临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23731, encryptionId=cccd23e31c0, topicName=乳腺癌临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Wed Oct 25 08:25:00 CST 2017, time=2017-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2031162, encodeId=00fe203116211, content=<a href='/topic/show?id=5df2460e269' target=_blank style='color:#2F92EE;'>#实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46072, encryptionId=5df2460e269, topicName=实践指南)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=796422, createdName=lvliquan, createdTime=Tue Aug 22 14:25:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319826, encodeId=097113198262c, content=<a href='/topic/show?id=c806125e30b' target=_blank style='color:#2F92EE;'>#NCCN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12573, encryptionId=c806125e30b, topicName=NCCN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323793, encodeId=496b1323e9316, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1572101, encodeId=9c8315e2101a7, content=<a href='/topic/show?id=413922e74cd' target=_blank style='color:#2F92EE;'>#临床实践指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22774, encryptionId=413922e74cd, topicName=临床实践指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=276d15780972, createdName=lily1621, createdTime=Sat Dec 31 00:25:00 CST 2016, time=2016-12-31, status=1, ipAttribution=)]

相关资讯

感动!医生在癌症术后二天,又去给病人做手术

医生在自己甲状腺癌术后二天,就披挂铅衣去做手术,只为不辜负病人对他的托付!

肺癌须知:国内治疗肺癌的一流医院

那么,国内肺癌治疗哪家强呢?今天小编为大家整理出十家国内治疗肺癌的一流医院,排名不分先后。PS:非专科医院以胸外科为介绍重点。

8种受欢迎的低碳水化合物饮食方式

低碳水化合物饮食已经流行了很多年, 它们曾经饱受争议,但是现在已经获得主流的接受度。

美国癌症协会:预防癌症的九点建议

每天我们都可以在医学网站和书刊上看到这样的报道:“某某食物可以预防癌症、某某饮食方式可以让你远离癌症。”然而,作为医学工作者和科研人员的我们禁不住要质疑这些传言到底有没有科学依据?

鼎臣咨询:中药企业如何做好中药新药研发?

在大多数中药企业不注重中药研发的时候,哪个中药企业积累了庞大的中药研发数据,基本就可以成为这一领域的巨头,因为这家药企会成为标准的制订者,更会形成与其他中药企业明显差异化的竞争态势。

虚不受补的中国医疗,如何调理?一位医生这么认为……

本文先说为什么“虚”,然后再说为什么不能大补,最后说怎么调理。

Baidu
map
Baidu
map
Baidu
map